Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

TriVerity™ for forbedret behandling av akuttmottakspasienter med mistenkt infeksjon (TIMED)

25. september 2026 oppdatert av: Inflammatix

A pre/post interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and/or the staging area/fast track area) with suspected infection and tachycardia or fever will be enrolled. Study conduct will be performed under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA). Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching, whereas participants in the post-phase will be managed incorporating the TriVerity™ Acute Infection and Sepsis Test results with standardized guidance for interpretation and resulting management actions. Many outcomes will be captured and compared between the pre- and post-phase phases including sepsis bundle compliance, patient disposition, appropriate use of antimicrobials (antibiotics and antivirals) and health economic findings. Safety measures for participants in the post-phase will include patient follow-up at predefined time points. The objective is to demonstrate improvement of patient management when incorporating the TriVerity Test result compared to standard of care. Improvements based on diagnostic (bacterial vs viral vs non-infectious inflammation) and prognostic (need for 7-day ICU level care) readouts of the TriVerity Test result will be tracked.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

320

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Illinois
      • Peoria, Illinois, Forente stater, 61637
        • OSF HealthCare Saint Francis Medical Center
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins Department of Emergency Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years

  2. Participant presents to ED with ALL of the below:

    2.1. Suspected acute infection (e.g., respiratory, urinary, abdominal, skin & soft-tissue infection, meningitis/encephalitis, or any other infection), and 2.2. Either heart rate >100 beats per minute or/and temperature >38C. 2.3. NOT immediately roomed in a primary designated treatment location,( i.e., they can be in the waiting room, ED triage hallways, and/or ED staging area/fast track area).

  3. Able to provide informed consent, or consent by legally authorized representative.

  4. Reachable via confirmed working cell phone (with backup contact number) and willing to respond to follow-up safety checks (see below for details).

Exclusion Criteria:

  1. Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to presentation in the waiting room of the ED. Participants will not be excluded for use of:

    1. Antiviral treatment for chronic viral infections, i.e., HIV, hepatitis B and hepatitis C
    2. Topical antibiotics, topical antivirals or topical antifungal agents
    3. Anti-herpes prophylaxis aiding suppression of a recuring herpes infection
    4. Single dose of one or combination of peri-operative (prophylactic) antibiotics
  2. Patients receiving palliative or hospice care, or those receiving limited interventional care (see Appendix B).

  3. Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient.

  4. Participants receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. Participants that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial.

  5. Participants previously enrolled in the present clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Pre-phase standard of care

Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching.

Eksperimentell: Post-phase TriVerity Test

Participants in the post-phase will be managed incorporating the TriVerity Test results with standardized guidance for interpretation and resulting management actions.

Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
SEP-1 bundle compliance
Tidsramme: Within 72 hours of ED admission

Mandatory hospital procedures for patients admitted with suspected sepsis

Within 72 hours of ED admission
Time to final ED disposition order
Tidsramme: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

Time from Triage (on Day 0) to the Time the ED physician orders the subject disposition (i.e., where the subject will go next: admittance or discharge).

Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percent of patients with antibiotics given in the ED combined with noninferior safety outcomes
Tidsramme: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

Calculated based on number of patients given antibiotics in ED

Date of enrollment (Day 0) to final Follow Up call (up to 35 days)
Emergency Department LOS
Tidsramme: Date of enrollment (Day 0) to final Follow Up call (up to 35 days)

Length of Stay

Date of enrollment (Day 0) to final Follow Up call (up to 35 days)
Diagnostic ordering practices
Tidsramme: Date of enrollment (Day 0) to 72 hours

Capturing the diagnostic ordering practices of attending physician (comparing physician choices and decisions before and after the TriVerity Test)

Date of enrollment (Day 0) to 72 hours
Hospital admission rates
Tidsramme: Date of enrollment (Day 0) to 72 hours

Overall admission rates for patients that meet study criteria from emergency department to other location (e.g., ICU)

Date of enrollment (Day 0) to 72 hours
Total hospital costs
Tidsramme: Date of enrollment (Day 0) to 28 days

Overall hospital costs for patients that meet study criteria

Date of enrollment (Day 0) to 28 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. november 2024

Primær fullføring (Faktiske)

10. mars 2026

Studiet fullført (Faktiske)

10. mars 2026

Datoer for studieregistrering

Først innsendt

5. september 2024

Først innsendt som oppfylte QC-kriteriene

9. oktober 2024

Først lagt ut (Faktiske)

15. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. september 2026

Sist bekreftet

1. februar 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere